EZH2 and myeloid neoplasm: A meta-analysis of 8 studies including 2243 patients that evaluates the correlation between EZH2 mutations and overall survival in patients with myeloid neoplasms shows that EZH2 mutations were associated with significantly worse overall survival (hazard ratio = 2.37, 95% confidential interval, 1.48-3.79) [33].